Case Study: Retrofitting Two New High-Purity Water Systems
GlaxoSmithKline (GSK)’s R&D Biopharmaceutical Pilot Plant in Upper Merion, PA is a R&D clinical trial material (CTM) manufacturing facility with an aggressive processing schedule that requires minimal shutdown interruptions. Utility reliability is paramount to achieve production demands and regulatory quality requirements. To meet the utility demands for increased CTM output, a capital investment project was required to replace the existing, obsolete high purity water (HPW) generation system and water-for-injection (WFI) generation system with new, reliable technology. This article describes how the new systems were designed and installed in a challenging space to ensure redundancy and improve sustainability.
Read this article from Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook.
View other articles in the 2017 Biologics and Sterile Drug Manufacturing eBook.
|
|---|
|
Columnists
 |
Ingredients Insider Cynthia ChallenerUnlocking the Best Solution for API Sourcing |
 |
Regulatory Watch Jill Wechsler Modern Manufacturing Key to More Effective Vaccines |
 |
EU Regulatory Watch Sean Milmo ICH Q12 Guidelines Spark Controversies |
Webcasts
Outsourcing
Lyophilization Scale-Up and Technical Transfer
Formulation and process development for injectable products are typically conducted at laboratory-scale. There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation is intended for lyophilization.
Catalent Adds Clinical Supplies Capacity
A $5.5-million expansion at its Philadelphia, PA clinical supplies facility gives Catalent additional packaging and storage capacity.
Cost Cutting to Drive 12% Growth in CRO Outsourcing Through 2021, New Study Finds
A new study by the Business Research Company reveals prominent contract research organization outsourcing trends.
Sponsored Links
